Peter J. O’Dwyer
Active 1985–2024
- Also published as
- Peter J O’Dwyer · Peter J. O'Dwyer
- 142
- Papers
- 31,251
- Citations
- 86
- h-index
- 139
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine55.3%
- Biochemistry, Genetics and Molecular Biology32.2%
- Immunology and Microbiology7.1%
- Neuroscience1.1%
- Engineering1.1%
- Materials Science0.7%
- Other2.5%
Topics
- Pancreatic and Hepatic Oncology Research4.1%
- Melanoma and MAPK Pathways3.9%
- Cancer Immunotherapy and Biomarkers3.9%
- Cancer Genomics and Diagnostics3.5%
- Colorectal Cancer Treatments and Studies3.1%
- Immune cells in cancer2.3%
- Other79.2%
Coauthors
- Keith T. Flaherty38
- Edith P. Mitchell25
- Stanley R. Hamilton24
- Robert J. Gray23
- Lisa M. McShane22
- Lyndsay N. Harris22
- Al B. Benson21
- Barbara A. Conley21
- David R. Patton21
- Alice P. Chen20
- Carlos L. Arteaga20
- Larry Rubinstein20
- P. Mickey Williams20
- Paul J. Catalano15
- James A. Zwiebel13
- Shuli Li12
- Maryann Gallagher11
- Bruce J. Giantonio10
- Victoria Wang10
- Angela DeMichele9
- Mark H. O’Hara9
- Ursina Teitelbaum9
- Andrea B. Troxel8
- Mark Rosen8
All papers
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
Authors: Mara H. Sherman, Ruth T. Yu, Dannielle D. Engle, Ning Ding, Annette R. Atkins, Hervé Tiriac, Eric A. Collisson, Frances Connor, Terry Van Dyke, С. В. Козлов, Philip Martin, Tiffany Tseng, David W. Dawson, Timothy R. Donahue, Atsushi Masamune, Tooru Shimosegawa, Minoti V. Apte, Jeremy S. Wilson, Beverly Ng, Sue Lynn Lau, Jenny E. Gunton, Geoffrey M. Wahl, Tony Hunter, Jeffrey A. Drebin, Peter J. O’Dwyer, Christopher Liddle, David A. Tuveson, Michael Downes, Ronald M. Evans - Cell 2014 cited by 1,137
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Authors: Gregory L. Beatty, E. Gabriela Chiorean, Matthew P. Fishman, Babak Saboury, Ursina Teitelbaum, Weijing Sun, Richard D. Huhn, Wenru Song, Dongguang Li, Leslie L. Sharp, Drew A. Torigian, Peter J. O’Dwyer, Robert H. Vonderheide - Science 2011 cited by 1,661
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Authors: Ryan B. Corcoran, Thierry André, Chloé E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Gary Middleton, Kei Muro, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O’Dwyer, Y. Humblet, Filip De Vos, A. Scott Jung, Jan C. Brase, Savina Jaeger, Severine Bettinger, Bijoyesh Mookerjee, Fatima Rangwala, Eric Van Cutsem - Cancer Discovery 2018 cited by 583
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
Authors: April K.S. Salama, Shuli Li, Erin Macrae, Jong‐In Park, Edith P. Mitchell, James A. Zwiebel, Helen X. Chen, Robert J. Gray, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Deborah K. Armstrong, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty - Journal of Clinical Oncology 2020 cited by 296
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Authors: Keith T. Flaherty, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Peter J. O’Dwyer, Richard J. Lee, Joseph F. Grippo, K. B. Nolop, Paul B. Chapman - New England Journal of Medicine 2010 cited by 3,536
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Authors: Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz - Journal of Clinical Oncology 2015 cited by 693
- The NCI-MATCH trial: lessons for precision oncology
Authors: Peter J. O’Dwyer, Robert J. Gray, Keith T. Flaherty, Alice P. Chen, Shuli Li, Victoria Wang, Lisa M. McShane, David R. Patton, James V. Tricoli, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Edith P. Mitchell, Naoko Takebe, David Sims, Brent Coffey, Tony Fu, Mark J. Routbort, Larry Rubinstein, Richard F. Little, Carlos L. Arteaga, Donna M. Marinucci, Stanley R. Hamilton, Barbara A. Conley, Lyndsay N. Harris, James H. Doroshow - Nature Medicine 2023 cited by 183
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
Authors: Pamela L. Kunz, Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, Edmond L. Schmulbach, Diane Reidy‐Lagunes, Jonathan Strosberg, Peter J. O’Dwyer, Al B. Benson - Journal of Clinical Oncology 2022 cited by 294
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Authors: Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Shuli Li, Lisa M. McShane, David R. Patton, Stanley R. Hamilton, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Edith P. Mitchell, Lyndsay N. Harris, Naoko Takebe, David Sims, Brent Coffey, Tony Fu, Mark J. Routbort, James A. Zwiebel, Larry Rubinstein, Richard F. Little, Carlos L. Arteaga, Robert L. Comis, Jeffrey S. Abrams, Peter J. O’Dwyer, Barbara A. Conley, for the NCI-MATCH team - Journal of Clinical Oncology 2020 cited by 295
- Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Authors: Mark Sausen, Jillian Phallen, Vilmos Adleff, Siân Jones, Rebecca Leary, Michael T. Barrett, Valsamo Anagnostou, Sonya Parpart-Li, Derek Murphy, Qing Kay Li, Carolyn Hruban, Rob Scharpf, James R. White, Peter J. O’Dwyer, Peter J. Allen, James R. Eshleman, Craig B. Thompson, David S. Klimstra, David C. Linehan, Anirban Maitra, Ralph H. Hruban, Luis A. Díaz, Daniel D. Von Hoff, Julia S. Johansen, Jeffrey A. Drebin, Victor E. Velculescu - Nature Communications 2015 cited by 484
- Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Authors: Zev A. Wainberg, Howard S. Höchster, Edward Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David Waterhouse, Martin Guiterrez, Aparna R. Parikh, Rishi Jain, Daniel R. Carrizosa, Hatem Soliman, Thomas Lila, David J. Reiss, Daniel W. Pierce, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Peter J. O’Dwyer - Clinical Cancer Research 2020 cited by 154
- First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Authors: Gregory L. Beatty, Peter J. O’Dwyer, Jason Clark, Jack Shi, Kevin Bowman, Peggy Scherle, Robert Newton, Richard Schaub, Janet Maleski, Lance Leopold, Thomas F. Gajewski - Clinical Cancer Research 2017 cited by 318
- Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
Authors: Thomas B. Karasic, Mark H. O’Hara, Arturo Loaiza‐Bonilla, Kim A. Reiss, Ursina Teitelbaum, Erkut Borazanci, Ana De Jesus‐Acosta, Colleen Redlinger, Jessica Burrell, Daniel A. Laheru, Daniel D. Von Hoff, Ravi K. Amaravadi, Jeffrey A. Drebin, Peter J. O’Dwyer - JAMA Oncology 2019 cited by 290
- Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
Authors: Anthony B. El-Khoueiry, James S. Clarke, Tobias Neff, T. Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido‐Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak - British Journal of Cancer 2023 cited by 74
- Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Authors: Ana De Jesus‐Acosta, Elizabeth A. Sugar, Peter J. O’Dwyer, Ramesh K. Ramanathan, Daniel D. Von Hoff, Zeshaan A. Rasheed, Lei Zheng, Asma Begum, Robert A. Anders, Anirban Maitra, Florencia McAllister, N.V. Rajeshkumar, Shinichi Yabuuchi, Roeland F. de Wilde, Bhavina Batukbhai, İsmet Şahin, Daniel A. Laheru - British Journal of Cancer 2019 cited by 170
- A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
Authors: Myrna R. Rosenfeld, Xiaobu Ye, Jeffrey G. Supko, Serena Desideri, Stuart A. Grossman, Steven Brem, Tom Mikkelson, Daniel Wang, Yunyoung C Chang, Janice Hu, Quentin McAfee, Joy Fisher, Andrea B. Troxel, Shengfu Piao, Daniel F. Heitjan, Kay-See Tan, Laura Pontiggia, Peter J. O’Dwyer, Lisa E. Davis, Ravi K. Amaravadi - Autophagy 2014 cited by 528
- Combined MTOR and autophagy inhibition
Authors: Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M. Algazy, Tracey L. Evans, Leslie A. Fecher, Lynn M. Schuchter, Drew A. Torigian, Jeffrey T Panosian, Andrea B. Troxel, Kay-See Tan, Daniel F. Heitjan, Angela DeMichele, David J. Vaughn, Maryann Redlinger, Abass Alavi, Jonathon Kaiser, Laura Pontiggia, Lisa E. Davis, Peter J. O’Dwyer, Ravi K. Amaravadi - Autophagy 2014 cited by 419
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Authors: Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Peter J. O’Dwyer, Edith P. Mitchell, Steven R. Alberts, Michael Schwartz, Al B. Benson - Journal of Clinical Oncology 2007 cited by 2,272
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Authors: Komal Jhaveri, X.V. Wang, Vicky Makker, Shiuh‐Wen Luoh, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Robert J. Gray, S. Li, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, A.P. Chen, Keith T. Flaherty - Annals of Oncology 2019 cited by 143
- Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Authors: Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John J. Wright, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jennifer M. Suga, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty - Journal of Clinical Oncology 2022 cited by 72
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Authors: Gregory L. Beatty, Drew A. Torigian, E. Gabriela Chiorean, Babak Saboury, Alex Brothers, Abass Alavi, Andrea B. Troxel, Weijing Sun, Ursina Teitelbaum, Robert H. Vonderheide, Peter J. O’Dwyer - Clinical Cancer Research 2013 cited by 452
- The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Authors: Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton, P. Mickey Williams, Edith P. Mitchell, A. John Iafrate, Jeffrey Sklar, Lyndsay N. Harris, Lisa M. McShane, Larry Rubinstein, David Sims, Mark Routbort, Brent Coffey, Tony Fu, James A. Zwiebel, Richard F. Little, Donna M. Marinucci, Robert B. Catalano, Rick Magnan, Warren A. Kibbe, Carol J. Weil, James V. Tricoli, Brian M. Alexander, Shaji Kumar, Gary K. Schwartz, Funda Meric‐Bernstam, Chih‐Jian Lih, Worta McCaskill‐Stevens, Paolo F. Caimi, Naoko Takebe, Vivekananda Datta, Carlos L. Arteaga, Jeffrey S. Abrams, Robert L. Comis, Peter J O’Dwyer, Barbara A. Conley, for the NCI-MATCH Team - JNCI Journal of the National Cancer Institute 2020 cited by 228
- Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma
Authors: Rebecca L. Porter, Neelima K. C. Magnus, Vishal Thapar, Robert Morris, Annamária Szabolcs, Azfar Neyaz, Anupriya S. Kulkarni, Eric C. Tai, Abhijit Chougule, Alessandra Hillis, Gabriel Golczer, Hongshan Guo, Teppei Yamada, Tomohiro Kurokawa, Chittampalli N. Yashaswini, Matteo Ligorio, Kevin D. Vo, Linda T. Nieman, Andrew S. Liss, Vikram Deshpande, Michael S. Lawrence, Shyamala Maheswaran, Carlos Fernández-del Castillo, Theodore S. Hong, David P. Ryan, Peter J. O’Dwyer, Jeffrey A. Drebin, Cristina R. Ferrone, Daniel A. Haber, David T. Ting - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 128
- Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Authors: Max M. Wattenberg, Daniella Asch, Shun Yu, Peter J. O’Dwyer, Susan M. Domchek, Katherine L. Nathanson, Mark Rosen, Gregory L. Beatty, Evan S. Siegelman, Kim A. Reiss - British Journal of Cancer 2019 cited by 206
